medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-10-51-57medalphabet-3162Research ArticleСтатьиОбновленный анализ – исследование OlympiA: шанс на излечение при раннем и местнораспространенном gBRCA- ассоциированном раке молочной железыUpdated analysis – OlympiA study: Chance of cure in early and locally advanced gBRCA-associated breast cancerhttps://orcid.org/0000-0001-5289-7866ЛубенниковаЕ. В.LubennikovaE. V.

 Лубенникова Елена Владимировна, к. м. н., с. н. с. отделения лекарственных методов лечения № 1

 Москва

Lubennikova Elena V., PhD Med, senior researcher at Dept of Medicinal Methods of Treatment № 1

 Moscow

lubennikova@yandex.ruhttps://orcid.org/0000-0001-7728-9533АртамоноваЕ. В.ArtamonovaE. V.

Артамонова Елена Владимировна, д. м. н., зав. отделением лекарственных методов лечения № 1 , проф. кафедры онкологии и лучевой терапии, зав.кафедрой онкологии и торакальной хирургии

 Москва

Artamonova Elena V., DM Sci (habil.), head of Dept of Medicinal Methods of Treatment № 1 , professor at Dept of Oncology and Radiation Therapy, head of Dept of Oncology and Thoracic Surgery.Moscow

artamonovae@mail.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N. N. BlokhinRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»РоссияNational Medical Research Centre of Oncology n.a. N. N. Blokhin; Russian National Research Medical University n.a. N. I. Pirogov; Moscow Regional Research Clinical Institute n.a. M. F. VladimirskyRussian Federation202329062023010Диагностика и онкотерапия (1)5157Copyright © Лубенникова Е.В., Артамонова Е.В., 20232023Лубенникова Е.В., Артамонова Е.В.Lubennikova E.V., Artamonova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3162

В течение последних лет ингибиторы PARP успешно применяются в лечении BRCA-ассоциированного метастатического рака молочной железы. Новым показанием для применения олапариба стала адъювантная терапия раннего и местнораспространенного HER 2-отрицательного рака молочной железы высокого риска с герминальными мутациями генов BRCA1/2. В данной публикации освещены результаты обновленного анализа исследования OlympiA, изменившие клиническую практику. Адъювантная терапия олапарибом в течение 1 года значимо повысила показатели выживаемости: так, iDFS достигла 82,7 % против 75,4 % в контрольной группе, а ОВ – 89,8 % против 86,4 % соответственно. Лечение обладает благоприятным профилем безопасности и не снижает качество жизни. Несмотря на впечатляющие результаты, исследование OlympiA порождает множество вопросов о возможностях интеграции PARP-ингибиторов в современные стандарты лечения раннего РМЖ. Основные спорные моменты и во зможные пути их разрешения рассмотрены в данном обзоре.

PARP inhibitors have been successfully used in the treatment of BRCA-associated metastatic breast cancer in recent years. Adjuvant therapy for gBRCAm carriers with HER 2-negative high-risk early-stage breast cancer has become a new indication for the use of olaparib.

This publication highlights the results of an updated analysis of the OlympiA trial that has changed clinical practice. Adjuvant treatment with olaparib for 1 year signifiantly increased survival rates. Four-year IDFS for the olaparib group was 82.7 % vs 75.4 % for placebo group.

Four-year OS was 89.8 % in the olaparib group and 86.4 % in the placebo group. The treatment has a favorable safety profie and does not reduce quality of life. Despite impressive results the OlympiA study raises many questions about the possibilities of integrating PARP inhibitors into modern standards for the treatment of early breast cancer. The main points of contention and possible ways to resolve them are discussed in this review.

рак молочной железымутации BRCAPARP-ингибиторыолапарибтрижды негативный рак молочной железыHER 2-отрицательный рак молочной железыадъювантная терапия рака молочной железы.breast cancerBRCA mutationPARP inhibitorsolaparibtriple-negative breast cancerHER 2-negative breast canceradjuvant therapy for breast cancerReferencesRay-Coquard I., Pérol D., Pujade-Lauraine E. PARP Inhibitors in Ovarian Cancer. Reply. The New England Journal of Medicine. 2020; 382 (16): 1574–1575. https://doi.org/10.1056/nejmc2000644Ray-Coquard I., Pérol D., Pujade-Lauraine E. PARP Inhibitors in Ovarian Cancer. Reply. The New England Journal of Medicine. 2020; 382 (16): 1574–1575. https://doi.org/10.1056/nejmc2000644Pujade-Lauraine E., Ledermann J. A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017; 18 (9): 1274–1284. https://doi.org/10.1016/S 1470–2045(17)30469–2Pujade-Lauraine E., Ledermann J. A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017; 18 (9): 1274–1284. https://doi.org/10.1016/S 1470–2045(17)30469–2González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/NEJMoa1910962González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/NEJMoa1910962Del Campo J. M., Matulonis U. A., Malander S., et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology. 2019; 37 (32): 2968–2973. https://doi.org/10.1200/jco.18.02238Del Campo J. M., Matulonis U. A., Malander S., et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology. 2019; 37 (32): 2968–2973. https://doi.org/10.1200/jco.18.02238Артамонова Е. В., Коваленко Е. И., Снеговой А. В., et al. Олапариб в поддерживающей терапии платиночувствительных рецидивов BRCA-ассоциированного рака яичников в реальной клинической практике: первые результаты наблюдательного исследования в российской популяции пациенток. Современная онкология. 2018; 20 (3): 19–25. https://doi.org/10.26442/1815–1434_2018.3.19–25Артамонова Е. В., Коваленко Е. И., Снеговой А. В., et al. Олапариб в поддерживающей терапии платиночувствительных рецидивов BRCA-ассоциированного рака яичников в реальной клинической практике: первые результаты наблюдательного исследования в российской популяции пациенток. Современная онкология. 2018; 20 (3): 19–25. https://doi.org/10.26442/1815–1434_2018.3.19–25Artamonova E. V., Kovalenko E. I., Snegovoy A. V., et al. Olaparib in maintenance therapy of platinum-sensitive relapses of BRCA-associated ovarian cancer in real clinical practice: First results of an observational study in the Russian patient population. Modern oncology. 2018; 20 (3): 19–25. https://doi.org/10.26442/181 5–1434_2018.3.19–25Artamonova E. V., Kovalenko E. I., Snegovoy A. V., et al. Olaparib in maintenance therapy of platinum-sensitive relapses of BRCA-associated ovarian cancer in real clinical practice: First results of an observational study in the Russian patient population. Modern oncology. 2018; 20 (3): 19–25. https://doi.org/10.26442/181 5–1434_2018.3.19–25Golan T., Hammel P., Reni M., et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine. 2019; 381 (4): 317–327. https://doi.org/10.1056/NEJMoa1903387Golan T., Hammel P., Reni M., et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine. 2019; 381 (4): 317–327. https://doi.org/10.1056/NEJMoa1903387de Bono J., Mateo J., Fizazi K., et al. Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine. 2020; 382 (22): 2091–2102. https://doi.org/10.1056/NEJMoa1903387de Bono J., Mateo J., Fizazi K., et al. Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine. 2020; 382 (22): 2091–2102. https://doi.org/10.1056/NEJMoa1903387Матвеев В. Б., Халмурзаев О. А., Евсюкова О. И. et al. Международный опыт применения олапариба при метастатическом кастрационно-резистентном раке предстательной железы: обзор литературы. Онкоурология. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206Матвеев В. Б., Халмурзаев О. А., Евсюкова О. И. et al. Международный опыт применения олапариба при метастатическом кастрационно-резистентном раке предстательной железы: обзор литературы. Онкоурология. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206Matveev V. B., Khalmurzaev O. A., Evsyukova O. I. et al. International experience with olaparib in metastatic castration-resistant prostate cancer: a review of the literature. Oncourology. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206Matveev V. B., Khalmurzaev O. A., Evsyukova O. I. et al. International experience with olaparib in metastatic castration-resistant prostate cancer: a review of the literature. Oncourology. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206Robson M., Im S. A., Senkus E., Xu B., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine. 2017; 377 (6): 523–533. https://doi.org/10.1056/nejmoa1706450Robson M., Im S. A., Senkus E., Xu B., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine. 2017; 377 (6): 523–533. https://doi.org/10.1056/nejmoa1706450Litton J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018). Litton J. K., Rugo H. S., Ettl J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine. 2018; 379 (8): 753–763. https://doi.org/10.1056/nejmoa1802905Litton J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018). Litton J. K., Rugo H. S., Ettl J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine. 2018; 379 (8): 753–763. https://doi.org/10.1056/nejmoa1802905Tutt A. N., Garber J. E., Kaufman B., et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. New England Journal of Medicine. 2021; 384 (25): 2394–2405. https://doi.org/10.1056/NEJMoa2105215Tutt A. N., Garber J. E., Kaufman B., et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. New England Journal of Medicine. 2021; 384 (25): 2394–2405. https://doi.org/10.1056/NEJMoa2105215Tutt A. N.J.; Garber J.; Gelber R. D. et al. Prespecifid Event-Driven Analysis of Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Germline BRCA1/2 Mutation Associated Breast Cancer. In ESMO Virtual Plenary. Abstract VP1–2022; ESMO: Lugano, Switzerland, 2022.Tutt A. N.J.; Garber J.; Gelber R. D. et al. Prespecifid Event-Driven Analysis of Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Germline BRCA1/2 Mutation Associated Breast Cancer. In ESMO Virtual Plenary. Abstract VP1–2022; ESMO: Lugano, Switzerland, 2022.Geyer Jr C. E., Garber J. E., Gelber R. D., et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of oncology. 2022; 33 (12): 1250–1268. https://doi.org/10.1016/j.annonc.2022.09.159Geyer Jr C. E., Garber J. E., Gelber R. D., et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of oncology. 2022; 33 (12): 1250–1268. https://doi.org/10.1016/j.annonc.2022.09.159Atchley D. P., Albarracin C. T., Lopez A., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26 (26): 4282–8. https://doi.org//10.1200/JCO.2008.16.6231Atchley D. P., Albarracin C. T., Lopez A., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26 (26): 4282–8. https://doi.org//10.1200/JCO.2008.16.6231Beitsch P. D., Whitworth P. W., Hughes K., et al. Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? Journal of Clinical Oncology. 2019; 37 (6): 453–460. https://doi.org/10.1200/JCO.18.01631Beitsch P. D., Whitworth P. W., Hughes K., et al. Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? Journal of Clinical Oncology. 2019; 37 (6): 453–460. https://doi.org/10.1200/JCO.18.01631Yadav S., Hu C., Hart S. N., et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. Journal of Clinical Oncology. 2020; 38 (13): 1409–1418. https://doi.org/10.1200/jco.19.02190Yadav S., Hu C., Hart S. N., et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. Journal of Clinical Oncology. 2020; 38 (13): 1409–1418. https://doi.org/10.1200/jco.19.02190Kurian AW, Griffih KA, Hamilton AS, et al. Genetic Testing and Counseling Among Patients with Newly Diagnosed Breast Cancer. JAMA. 2017; 317 (5): 531–534. https://doi.org/10.1001/jama.2016.16918Kurian AW, Griffih KA, Hamilton AS, et al. Genetic Testing and Counseling Among Patients with Newly Diagnosed Breast Cancer. JAMA. 2017; 317 (5): 531–534. https://doi.org/10.1001/jama.2016.16918Kurian A. W., Ward K. C., Howlader N., et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. Journal of Clinical Oncology. 2019; 37 (15): 1305–1315. https://doi.org/10.1200/jco.18.01854Kurian A. W., Ward K. C., Howlader N., et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. Journal of Clinical Oncology. 2019; 37 (15): 1305–1315. https://doi.org/10.1200/jco.18.01854Childers C. P., Childers K. K., Maggard-Gibbons M., et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. Journal of Clinical Oncology. 2017; 35 (34): 3800–3806. https://doi.org/10.1200/jco.2017.73.6314Childers C. P., Childers K. K., Maggard-Gibbons M., et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. Journal of Clinical Oncology. 2017; 35 (34): 3800–3806. https://doi.org/10.1200/jco.2017.73.6314McCarthy A.M., Bristol M., Domchek S. M., et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. Journal of Clinical Oncology. 2016; 34 (22): 2610–2618. https://doi.org/10.1200/jco.2015.66.0019McCarthy A.M., Bristol M., Domchek S. M., et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. Journal of Clinical Oncology. 2016; 34 (22): 2610–2618. https://doi.org/10.1200/jco.2015.66.0019Knerr S., Bowles E. J., Leppig K. A., et al. Trends in BRCA test utilization in an integrated health system, 2005–2015. JNCI: Journal of the National Cancer Institute. 2019; 111 (8): 795–802. https://doi.org/10.1093/jnci/djz008Knerr S., Bowles E. J., Leppig K. A., et al. Trends in BRCA test utilization in an integrated health system, 2005–2015. JNCI: Journal of the National Cancer Institute. 2019; 111 (8): 795–802. https://doi.org/10.1093/jnci/djz008Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376 (22): 2147–2159. https://doi.org/10.1056/nejmoa1612645Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376 (22): 2147–2159. https://doi.org/10.1056/nejmoa1612645van Mackelenbergh MT, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy e a meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022; 166: 185–201. https://doi.org/10.1016/j.ejca.2022.02.003van Mackelenbergh MT, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy e a meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022; 166: 185–201. https://doi.org/10.1016/j.ejca.2022.02.003Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003–11_CIBOMA/2004–01). J Clin Oncol. 2020; 38 (3): 203–213. https://doi.org/10.1200/jco.19.00904Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003–11_CIBOMA/2004–01). J Clin Oncol. 2020; 38 (3): 203–213. https://doi.org/10.1200/jco.19.00904Tung N. M., Zakalik D., Somerfild M. R. Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients with High-Risk Early-Stage HER 2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J. Clin. Oncol. 2021, 39, 2959–2961. https://doi.org/10.1200/jco.21.01532Tung N. M., Zakalik D., Somerfild M. R. Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients with High-Risk Early-Stage HER 2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J. Clin. Oncol. 2021, 39, 2959–2961. https://doi.org/10.1200/jco.21.01532Johnston S. R., Toi M., O’Shaughnessy J., et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER 2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2023; 24 (1): 77–90. https://doi.org/10.1016/s1470–2045(22)00694–5Johnston S. R., Toi M., O’Shaughnessy J., et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER 2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2023; 24 (1): 77–90. https://doi.org/10.1016/s1470–2045(22)00694–5Johnston S. R., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER 2–, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology. 2020; 38 (34); 3987–3998. https://doi.org/10.1200/jco.20.02514Johnston S. R., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER 2–, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology. 2020; 38 (34); 3987–3998. https://doi.org/10.1200/jco.20.02514Safonov A, Bandlamudi C, Tallon de Lara P, et al. Comprehensive genomic profiing of patients with breast cancer identifis germlinesomatic interactions mediating therapy resistance. SABCS. 2021; 82 (suppl 4): abstr GS 4–08.Safonov A, Bandlamudi C, Tallon de Lara P, et al. Comprehensive genomic profiing of patients with breast cancer identifis germlinesomatic interactions mediating therapy resistance. SABCS. 2021; 82 (suppl 4): abstr GS 4–08.Kim JY, Oh JM, Park YH, et al. Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the fist-line treatment for hormone receptor-positive, HER 2-negative advanced breast cancer? Front Oncol. 2021; 11: 759150. https://doi.org/10.3389/fonc.2021.759150Kim JY, Oh JM, Park YH, et al. Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the fist-line treatment for hormone receptor-positive, HER 2-negative advanced breast cancer? Front Oncol. 2021; 11: 759150. https://doi.org/10.3389/fonc.2021.759150Bruno L, Ostinelli A, Waisberg F, et al. Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes. JCO Precis Oncol. 2022; 6: e2100140. https://doi.org/10.1200/po.21.00140Bruno L, Ostinelli A, Waisberg F, et al. Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes. JCO Precis Oncol. 2022; 6: e2100140. https://doi.org/10.1200/po.21.00140Tung N., Garber J. E. PARP inhibition in breast cancer: Progress made and future hopes. NPJ Breast Cancer. 2022; 8 (1); 47. https://doi.org/10.1038/s41523–022–00411–3Tung N., Garber J. E. PARP inhibition in breast cancer: Progress made and future hopes. NPJ Breast Cancer. 2022; 8 (1); 47. https://doi.org/10.1038/s41523–022–00411–3Iwamoto T., Booser D., Valero V., et al Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30 (7): 729–734. https://doi.org/10.1200/jco.2011.38.9619Iwamoto T., Booser D., Valero V., et al Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30 (7): 729–734. https://doi.org/10.1200/jco.2011.38.9619Deyarmin B., Kane J. L., Valente A. L., et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Annals of Surgical Oncology. 2013; 20: 87–93. https://doi.org/10.1245/s10434–012–2588–8Deyarmin B., Kane J. L., Valente A. L., et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Annals of Surgical Oncology. 2013; 20: 87–93. https://doi.org/10.1245/s10434–012–2588–8Gloyeske N. C., Dabbs D. J. Bhargava R. Low ER+ breast cancer: Is this a distinct group? Am. J. Clin. Pathol. 141, 697–701 (2014). https://doi.org/10.1309/ajcp-34cysatwfdpqGloyeske N. C., Dabbs D. J. Bhargava R. Low ER+ breast cancer: Is this a distinct group? Am. J. Clin. Pathol. 141, 697–701 (2014). https://doi.org/10.1309/ajcp-34cysatwfdpqMoore K., Colombo N., Scambia G., et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2018; 379 (26): 2495–2505. https://doi.org/10.1056/nejmoa1810858Moore K., Colombo N., Scambia G., et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2018; 379 (26): 2495–2505. https://doi.org/10.1056/nejmoa1810858Gonzalez-Martin A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019). González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/nejmoa1910962Gonzalez-Martin A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019). González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/nejmoa1910962Madariaga A, Bowering V, Ahrari S, et al. Manage wisely: poly (ADPribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020; 30 (7): 903–915. http://dx.doi.org/10.1136/ijgc-2020–001288Madariaga A, Bowering V, Ahrari S, et al. Manage wisely: poly (ADPribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020; 30 (7): 903–915. http://dx.doi.org/10.1136/ijgc-2020–001288Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specifi survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 1956–62. https://doi.org/10.1200/jco.2010.31.8469Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specifi survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 1956–62. https://doi.org/10.1200/jco.2010.31.8469

The authors declare that there are no conflicts of interest present.